Canaccord Genuity resumed coverage on Rezolute with a new price target
$RZLT
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity resumed coverage of Rezolute with a rating of Buy and set a new price target of $17.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $12.00 | Outperform | Wedbush |
| 8/27/2024 | $11.00 | Buy | Guggenheim |
| 7/17/2024 | $13.00 | Buy | BTIG Research |
| 6/4/2024 | $14.00 | Buy | Craig Hallum |
| 4/9/2024 | $8.00 | Buy | Maxim Group |
| 8/2/2022 | $17.00 | Buy | Canaccord Genuity |
| 6/15/2022 | $9.00 | Overweight | Cantor Fitzgerald |
| 11/29/2021 | $30.00 → $17.00 | Buy | Canaccord Genuity |
8-K - Rezolute, Inc. (0001509261) (Filer)
10-Q - Rezolute, Inc. (0001509261) (Filer)
8-K - Rezolute, Inc. (0001509261) (Filer)
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of October 31, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Rezolute. The Company granted options to purchase 245,000 shares, in the aggregate, of Rezolute common stock to the new employees. The options h
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the three months ended September 30, 2025. "We remain on track to report topline results from the Phase 3 sunRIZE trial in congenital hyperinsulinism in December," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "In tumor hyperinsulinism, following FDA alignment on our streamlined Phase 3 trial and with enrollment now underway, we expect to both complete enrollment and report topline data i
REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the company will host a virtual investor event via webcast on Monday, November 10, 2025, from 12:00 – 1:30 pm EST. The event will highlight the market opportunity and clinical development of ersodetug, which is currently being evaluated in two Phase 3 studies in congenital hyperinsulinism (HI) and tumor HI, respectively. During the event, Rezolute Chief Commercial Officer, Sunil Karnawat, will discuss the anticipated commercial opportunities for ersodetug as a p
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
3 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00
Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00
BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00
REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p
SC 13G/A - Rezolute, Inc. (0001509261) (Subject)
SC 13G/A - Rezolute, Inc. (0001509261) (Subject)
SC 13G/A - Rezolute, Inc. (0001509261) (Subject)
REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the company will host a virtual investor event via webcast on Monday, November 10, 2025, from 12:00 – 1:30 pm EST. The event will highlight the market opportunity and clinical development of ersodetug, which is currently being evaluated in two Phase 3 studies in congenital hyperinsulinism (HI) and tumor HI, respectively. During the event, Rezolute Chief Commercial Officer, Sunil Karnawat, will discuss the anticipated commercial opportunities for ersodetug as a p
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. "We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "We also anticipate completing enrollment this quarter for our o